Transcriptional repression of the neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein

Molecular and Cellular Biology

Volumn 25, Issue 14, 2005, Pages 5869-5879

  Yang, Genyan ^a   Khalaf, Waleed ^c   Van De Locht, Louis ^d   Jansen, Joop H ^d   Gao, Meihua ^f   Thompson, Mary Ann ^a   Van Der Reijden, Bert A ^d   Gutmann, David H ^g   Delwel, Ruud ^e   Clapp, D Wade ^c   Hiebert, Scott W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^f MIDDLE TENNESSEE STATE UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HYBRID PROTEIN; PROTEIN MTG8; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 21744434372     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.14.5869-5879.2005     Document Type: Article

References (67)

1. Adya, N., T. Stacy, N. A. Speck, and P. P. Liu. 1998. The leukemic protein core binding factor β (CBFβ)-smooth-muscle myosin heavy chain sequesters CBFα2 into cytoskeletal filaments and aggregates. Mol. Cell. Biol. 18:7432-7443.
2. Amann, J. M., J. Nip, D. K. Strom, B. Lutterbach, H. Harada, N, Lenny, J. R. Downing, S. Meyers, and S. W. Hiebert. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21:6470-6483.
3. Bajenaru, M. L., J. Donahoe, T. Corral, K. M. Reilly, S. Brophy, A. Pellicer, and D. H. Gutmann. 2001. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 33:314-323.
4. Beghini, A., C. B. Ripamonti, R. Cairoli, G. Cazzaniga, P. Colapietro, F. Elice, G. Nadali, G. Grillo, O. A. Haas, A. Biondi, E. Morra, and L. Larizza. 2004. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 89:920-925.
5. Bollag, G., D. W. Clapp, S. Shih, F. Adler, Y. Y. Zhang, P. Thompson, B. J. Lange, M. H. Freedman, F. McCormick, T. Jacks, and K. Shannon. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12:144-148.
6. Bosselut, R., J. F. Duvall, A. Gegonne, M. Bailly, A. Hemar, J. Brady, and J. Ghysdael. 1990. The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1. EMBO J. 9:3137-3144.
7. Brannan, C. I., A. S. Perkins, K. S. Vogel, N. Ratner, M. L. Nordlund, S. W. Reid, A. M. Buchberg, N. A. Jenkins, L. F. Parada, and N. G. Copeland. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 8:1019-1029. (Erratum, 8:2792, 1994.)
8. Burel, S. A., N. Harakawa, L. Zhou, T. Pabst, D. G. Tenen, and D. E. Zhang. 2001. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol. Cell. Biol. 21:5577-5590.
9. Cheung, V. G., L. K. Conlin, T. M. Weber, M. Arcaro, K. Y. Jen, M. Morley, and R. S. Spielman. 2003. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat. Genet. 33:422-425.
10. Daston, M. M., and N. Ratner. 1992. Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development. Dev. Dyn. 195:216-226.
11. H. DeClue, J. E., B. D. Cohen, and D. R. Lowy. 1991. Identification and characterization of the neurofibromatosis type 1 protein product. Proc. Natl. Acad. Sci. USA 88:9914-9918.
12. DeClue, J. E., A. G. Papageorge, J. A. Fletcher, S. R. Diehl, N. Ratner, W. C. Vass, and D. R. Lowy. 1992. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273.
13. Durst, K. L., B. Lutterbach, T. Kummalue, A. D. Friedman, and S. W. Hiebert. 2003. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol. Cell. Biol. 23:607-619.
14. Eischen, C. M., J. D. Weber, M. F. Roussel, C. J. Sherr, and J. L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:2658-2669.
15. Emanuel, P. D., L. J. Bates, R. P. Castleberry, R. J. Gualtieri, and K. S. Zuckerman. 1991. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77:925-929.
16. Feigenbaum, L., K. Fujita, F. S. Collins, and G. Jay. 1996. Repression of the NF1 gene by Tax may explain the development of neurofibromas in human T-lymphotropic virus type 1 transgenic mice. J. Virol. 70:3280-3285.
17. Gutmann, D. H., D. L. Wood, and F. S. Collins. 1991. Identification of the neurofibromatosis type 1 gene product. Proc. Natl. Acad. Sci. USA 88:9658-9662.
18. Hajra, A., A. Martin-Gallardo, S. A. Tarle, M. Freedman, S. Wilson-Gunn, A. Bernards, and F. S. Collins. 1994. DNA sequences in the promoter region of the NF1 gene are highly conserved between human and mouse. Genomics 21:649-652.
19. -/- hematopoietic stem cells and decreases the risk of clonal evolution. Blood 101:1299-1307.
20. -/- cells. J. Biol. Chem. 276:7240-7245.
21. Hildebrand, D., J. Tiefenbach, T. Heinzel, M. Grez, and A. B. Maurer. 2001. Multiple regions of eto cooperate in transcriptional repression. J. Biol. Chem. 276:9889-9895.
22. Hohaus, S., M. S. Petrovick, M. T. Voso, Z. Sun, D. E. Zhang, and D. G. Tenen. 1995. PU.1 (Spi-1) and C/EBPα regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol. Cell. Biol. 15:5830-5845.
23. Huang, G., K. Shigesada, K. Ito, H. J. Wee, T. Yokomizo, and Y. Ito. 2001. Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 20:723-733.
24. Huang, X., J. W. Peng, N. A. Speck, and J. H. Bushweller. 1999. Solution structure of core binding factor beta and map of the CBFα binding site. Nat. Struct. Biol. 6:624-627.
25. Ingram, D. A., K. Hiatt, A. J. King, L. Fisher, R. Shivakumar, C. Derstine, M. J. Wenning, B. Diaz, J. B. Travers, A. Hood, M. Marshall, D. A. Williams, and D. W. Clapp. 2001. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J. Exp. Med. 194:57-69.
26. Ingram, D. A., F. C. Yang, J. B. Travers, M. J. Wenning, K. Hiatt, S. New, A. Hood, K. Shannon, D. A. Williams, and D. W. Clapp. 2000. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J. Exp. Med. 191:181-188.
27. Ingram, D. A., L. Zhang, J. McCarthy, M. J. Wenning, L. Fisher, F. C. Yang, D. W. Clapp, and R. Kapur. 2002. Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences of Nf1 deficiency in T-cell development and function. Blood 100:3656-3662.
28. Jacks, T., T. S. Shih, E. M. Schmitt, R. T. Bronson, A. Bernards, and R. A. Weinberg. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 7:353-361.
29. Kaneko, H., S. Horiike, H. Nakai, Y. Ueda, M. Nakao, K. Hirakawa, S. Yokota, M. Taniwaki, S. Misawa, and K. Kashima. 1995. Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression. Int. J. Hematol. 61:113-116.
30. Kanno, Y., T. Kanno, C. Sakakura, S. C. Bae, and Y. Ito. 1998. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor α (CBFα) subunit by the leukemia-related PEBP2/CBFβ-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol. Cell. Biol. 18:4252-4261.
31. Kim, W. Y., M. Sieweke, E. Ogawa, H. J. Wee, U. Englmeier, T. Graf, and Y. Ito. 1999. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J. 18:1609-1620.
32. King, D., G. Yang, M. A. Thompson, and S. W. Hiebert. 2002. Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype. Oncogene 21:4978-4982.
33. Kohl, T. M., S. Schnittger, J. W. Ellwart, W. Hiddemann, and K. Spiekermann. 2005. KIT exon 8 mutations associated with core binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 105:3319-3321.
34. Langer, S. J., D. M. Bortner, M. F. Roussel, C. J. Sherr, and M. C. Ostrowski. 1992. Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol. Cell. Biol. 12:5355-5362.
35. Largaespada, D. A., C. I. Brannan, N. A. Jenkins, and N. G. Copeland. 1996. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat. Genet. 12:137-143.
36. Le, D. T., N. Kong, Y. Zhu, J. O. Lauchle, A. Aiyigari, B. S. Braun, E. Wang, S. C. Kogan, M. M. Le Beau, L. Parada, and K. M. Shannon. 2004. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103:4243-4250.
37. Lenny, N., S. Meyers, and S. W. Hiebert. 1995. Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene 11:1761-1769.
38. Levanon, D., R. E. Goldstein, Y. Bernstein, H. Tang, D. Goldenberg, S. Stifani, Z. Paroush, and Y. Groner. 1998. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc. Natl. Acad. Sci. USA 95:11590-11595.
39. Linggi, B., C. Muller-Tidow, L. van de Locht, M. Hu, J. Nip, H. Serve, W. E. Berdel, B. van der Reijden, D. E. Quelle, J. D. Rowley, J. Cleveland, J. H. Jansen, P. P. Pandolfi, and S. W. Hiebert. 2002. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med. 8:743-750.
40. Liu, P., S. A. Tarle, A. Hajra, D. F. Claxton, P. Marlton, M. Freedman, M. J. Siciliano, and F. S. Collins. 1993. Fusion between transcription factor CBFβ/ PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science 261:1041-1044.
41. Lu, D., R. Nounou, M. Beran, E. Estey, T. Manshouri, H. Kantarjian, M. J. Keating, and M. Albitar. 2003. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 97:441-449.
42. Ludwig, L., J. W. Janssen, A. S. Schulz, and C. R. Bartram. 1993. Mutations within the FLR exon of NF1 are rare in myelodysplastic syndromes and acute myelocytic leukemias. Leukemia 7:1058-1060.
43. Lutterbach, B., and S. W. Hiebert. 2000. Role of the transcription factor AML-I in acute leukemia and hematopoietic differentiation. Gene 245:223-235.
44. Lutterbach, B., Y. Hou, K. L. Durst, and S. W. Hiebert. 1999. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc. Natl. Acad. Sci. USA 96:12822-12827.
45. Lutterbach, B., D. Sun, J. Schuetz, and S. W. Hiebert. 1998. The MYND motif is required for repression of basal transcription from the multidrug resistance-1 promoter by the t(8;21) fusion protein. Mol. Cell. Biol. 18:3601-3611.
46. Lutterbach, B., J. J. Westendorf, B. Linggi, S. Isaac, E. Seto, and S. W. Hiebert. 2000. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J. Biol. Chem. 275:651-656.
47. Meyers, S., J. R. Downing, and S. W. Hiebert. 1993. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol. Cell. Biol. 13:6336-6345.
48. Morley, M., C. M. Molony, T. M. Weber, J. L. Devlin, K. G. Ewens, R. S. Spielman, and V. G. Cheung. 2004. Genetic analysis of genome-wide variation in human gene expression. Nature 430:743-747.
49. Mueller, B. U., T. Pabst, M. Osato, N. Asou, L. M. Johansen, M. D. Minden, G. Behre, W. Hiddemann, Y. Ito, and D. G. Tenen. 2002. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100:998-1007.
50. Nielsen, G. P., A. O. Stemmer-Rachamimov, Y. Ino, M. B. Moller, A. E. Rosenberg, and D. N. Louis. 1999. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/pl6 inactivation. Am. J. Pathol. 155:1879-1884.
51. Oleksiak, M. F., G. A. Churchill, and D. L. Crawford. 2002. Variation in gene expression within and among natural populations. Nat. Genet. 32:261-266.
52. Pabst, T., B. U. Mueller, N. Harakawa, C. Schoch, T. Haferlach, G. Behre, W. Hiddemann, D. E. Zhang, and D. G. Tenen. 2001. AML1-ETO down-regulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nat. Med. 7:444-451.
53. Pabst, T., B. U. Mueller, P. Zhang, H. S. Radomska, S. Narravula, S. Schnittger, G. Behre, W. Hiddemann, and D. G. Tenen. 2001. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPα), in acute myeloid leukemia. Nat. Genet. 27:263-270.
54. Petrovick, M. S., S. W. Hiebert, A. D. Friedman, C. J. Hetherington, D. G. Tenen, and D. E. Zhang. 1998. Multiple functional domains of AML1: PU.1 and C/EBPα synergize with different regions of AML1. Mol. Cell. Biol. 18:3915-3925.
55. Preudhomme, C., A. Vachee, B. Quesnel, E. Wattel, A. Cosson, and P. Fenaux. 1993. Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia 7:1071.
56. Quesnel, B., C. Preudhomme, M. Vanrumbeke, A. Vachee, J. L. Lai, and P. Fenaux. 1994. Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 8:878-880.
57. Rhoades, K. L., C. J. Hetherington, J. D. Rowley, S. W. Hiebert, G. Nucifora, D. G. Tenen, and D, E. Zhang. 1996. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc. Natl. Acad. Sci. USA 93:11895-11900.
58. Rowley, J. D. 1999. The role of chromosome translocations in leukemogenesis. Semin. Hematol. 36:59-72.
59. Shannon, K. M., P. O'Connell, G. A. Martin, D. Paderanga, K. Olson, P. Dinndorf, and F. McCormick. 1994. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N. Engl. J. Med. 330:597-601.
60. Side, L. E., P. D. Emanuel, B. Taylor, J. Franklin, P. Thompson, R. P. Castleberry, and K. M. Shannon. 1998. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 92:267-272.
61. Wallace, M. R., D. A. Marchuk, L. B. Andersen, R. Letcher, H. M. Odeh, A. M. Saulino, J. W. Fountain, A. Brereton, J. Nicholson, A. L. Mitchell, et al. 1990. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181-186. (Erratum, 250:1749, 1990.)
62. Wang, Y. Y., G. B. Zhou, T. Yin, B. Chen, J. Y. Shi, W. X. Liang, X. L. Jin, J. H. You, G. Yang, Z. X. Shen, J. Chen, S. M. Xiong, G. Q. Chen, F. Xu, Y. W. Liu, Z. Chen, and S. J. Chen. 2005. AML1-ETO and c-KIT mutation/ overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc. Natl. Acad. Sci. USA 102:1104-1109.
63. Weber, J. D., J. R. Jeffers, J. E. Rehg, D. H. Randle, G. Lozano, M. F. Roussel, C. J. Sherr, and G. P. Zambetti. 2000. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 14:2358-2365.
64. Westendorf, J. J., C. M. Yamamoto, N. Lenny, J. R. Downing, M. E. Selsted, and S. W. Hiebert. 1998. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-α, inhibits C/EBP-α-dependent transcription, and blocks granulocytic differentiation. Mol. Cell. Biol. 18:322-333.
65. Zhang, D. E., C. J. Hetherington, H. M. Chen, and D. G. Tenen. 1994. The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. Mol. Cell. Biol. 14:373-381.
66. Zhang, D. E., C. J. Hetherington, S. Meyers, K. L. Rhoades, C. J. Larson, H. M. Chen, S. W. Hiebert, and D. G. Tenen. 1996. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBFα2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol. Cell. Biol. 16:1231-1240.
67. Zhang, Y., B. R. Taylor, K. Shannon, and D. W. Clapp. 2001. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J. Clin. Investig. 108:709-715.